Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Amgen, Inc. (AMGN) Price & Performance

AbCellera Biologics IncTrade
Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Amgen, Inc. — how do they compare? AbCellera Biologics Inc trades at $8.93 (market cap $2.99B), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 75× AbCellera Biologics Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLAMGN
Market Cap
$2.99B$224.14B
Sector
HealthHealth
52-Week High
$9.76$417.20
52-Week Low
$2.78$271.18
Enterprise Value
$2.58B$267.45B
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN